Article
PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Aug 2012
Jensen J D, Knoop A, Laenkholm A V, Grauslund M, Jensen M B, Santoni-Rugiu E, Andersson M, Ewertz M
Abstract excerpt
BACKGROUND: This study was conducted to determine the frequency of PIK3CA mutations and human epidermal growth factor receptor-2 (HER2) phosphorylation status (pHER2-Tyr1221/1222) and if PIK3CA, phosphatase and tensin homolog (PTEN), or pHER2 has an impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. PATIENTS AND METHODS: Two hundred and forty...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.